Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects

INTRODUCTION: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, blocks cytokine signaling involved in psoriasis pathogenesis. This ethnic-bridging study evaluated deucravacitinib pharmacokinetics, tolerability, and safety in healthy Chinese subjects. METHODS: This phase I,...

Descripción completa

Detalles Bibliográficos
Autores principales: Jing, Shan, Lin, Yang, Dockens, Randy, Marchisin, David, He, Bing, Girgis, Ihab G., Chimalakonda, Anjaneya, Murthy, Bindu, Aras, Urvi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689320/
https://www.ncbi.nlm.nih.gov/pubmed/37981596
http://dx.doi.org/10.1007/s13555-023-01050-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689320/
https://www.ncbi.nlm.nih.gov/pubmed/37981596
http://dx.doi.org/10.1007/s13555-023-01050-7

Ejemplares similares